LMAT vs. NVCR, ATEC, ATRC, MDXG, AORT, FNA, SILK, NARI, ATRI, and KIDS
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include NovoCure (NVCR), Alphatec (ATEC), AtriCure (ATRC), MiMedx Group (MDXG), Artivion (AORT), Paragon 28 (FNA), Silk Road Medical (SILK), Inari Medical (NARI), Atrion (ATRI), and OrthoPediatrics (KIDS). These companies are all part of the "surgical & medical instruments" industry.
NovoCure (NASDAQ:NVCR) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.
LeMaitre Vascular has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
NovoCure presently has a consensus price target of $30.88, suggesting a potential upside of 117.58%. LeMaitre Vascular has a consensus price target of $69.33, suggesting a potential upside of 3.84%. Given LeMaitre Vascular's higher possible upside, research analysts clearly believe NovoCure is more favorable than LeMaitre Vascular.
In the previous week, NovoCure had 4 more articles in the media than LeMaitre Vascular. MarketBeat recorded 14 mentions for NovoCure and 10 mentions for LeMaitre Vascular. NovoCure's average media sentiment score of 0.62 beat LeMaitre Vascular's score of 0.30 indicating that LeMaitre Vascular is being referred to more favorably in the news media.
NovoCure has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
84.6% of NovoCure shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 5.7% of NovoCure shares are held by company insiders. Comparatively, 10.8% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
LeMaitre Vascular received 31 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 70.84% of users gave LeMaitre Vascular an outperform vote while only 63.71% of users gave NovoCure an outperform vote.
LeMaitre Vascular has a net margin of 15.56% compared to LeMaitre Vascular's net margin of -40.65%. NovoCure's return on equity of 10.57% beat LeMaitre Vascular's return on equity.
Summary
LeMaitre Vascular beats NovoCure on 14 of the 17 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
